Vinorelbine and Cisplatin for Metastatic Breast Cancer: A Salvage Regimen in Patients Progressing After Docetaxel and Anthracycline Treatment

Abstract

This cisplatin/VNR regimen is well tolerated and active in patients who failed anthracyclines and docetaxel treatment. The response rate, TTP, and survival data are high and indicate that cisplatin/VNR may have a place as salvage treatment in this group of patients. If these results can be verified in multi-institutional trials, this combination of drugs would merit investigation as part of a first-line therapy in breast cancer.